Pfizer Prices Bosulif With Eye Towards Leveling CML Playing Field
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer enters crowded competition for previously treated Ph+ chronic myelogenous leukemia with the newly approved bosutinib, but the firm hopes having a comparable price will level the playing field.
You may also be interested in...
Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial
Pfizer’s NDA for dual Src and Abl inhibitor bosutinib in previously-treated Philadelphia chromosome-positive CML bypassed the failed first-line Phase III BELA trial. In Europe, BELA is the basis of a pending front-line CML application.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.